Shots:
- The P-ll study involves assessing of ATYR1923 (1.0 & 3.0 mg/kg) vs PBO in 32 hospitalized COVID-19 patients in the ratio of (1:1:1) with severe respiratory complications who do not require mechanical ventilation in the US and Puerto Rico
- Result: the study met its 1EPs of safety, demonstrating that ATYR1923 (single dose, IV) was safe and well-tolerated in both treatment groups, with no SAEs, median time to recovery @3.0 mg/kg dose (5.5 vs 6 days); recovery by day 6 (83% vs 56%); median time to recovery @1.0 mg/kg dose (7days)
- The company is developing the therapy for patients with inflammatory lung diseases
Click here to read full press release/ article | Ref: Atyr Pharma | Image: American College of Cardiology
The post aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications first appeared on PharmaShots.
